Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Randomized Trial of the Family Intervention: Telephone Tracking-Caregiver for Dementia Caregivers: Use of Community and Healthcare Resources.

Journal of the American Geriatrics Society·2016

Same author

Families and stroke: The clinical implications of research findings.

Topics in stroke rehabilitation·2016

Same author

Depression and stroke.

Topics in stroke rehabilitation·2016

Same author

Psychobehavioral problems other than depression in stroke.

Topics in stroke rehabilitation·2016

Same author

Foreword.

Topics in stroke rehabilitation·2016

Same author

Psychosocial telephone intervention for dementia caregivers: A randomized, controlled trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2014

Search research articles

Related Experiment Video

Updated: Mar 14, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Psychopharmacology and stroke.

Duane S Bishop¹, Russell Pet²

¹a Psychiatric Consultant Southern New England Rehabilitation Center Assistant Professor, Psychiatry and Human Behavior Brown University Providence , Rhode Island Psychiatrist St Luke's Hospital New Bedford , Massachusetts.

Topics in Stroke Rehabilitation

|September 30, 2016

Summary

Psychopharmacology in stroke patients demands precise diagnosis and medication management to aid recovery. This review details the clinical use of various psychotropic drugs, including antipsychotics and antidepressants, for stroke patients.

Keywords:

antidepressant antipsychotic anxiolytic medication psychopharmacology psychostimulant review stroke

More Related Videos

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

Gathering Self-Initiated Rat Behavioral Data to Characterize Post-Stroke Deficits

Gathering Self-Initiated Rat Behavioral Data to Characterize Post-Stroke Deficits

Published on: March 15, 2024

Related Experiment Videos

Last Updated: Mar 14, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

Gathering Self-Initiated Rat Behavioral Data to Characterize Post-Stroke Deficits

Gathering Self-Initiated Rat Behavioral Data to Characterize Post-Stroke Deficits

Published on: March 15, 2024

Area of Science:

Neuroscience
Psychiatry
Clinical Pharmacology

Background:

Stroke can lead to various psychiatric complications requiring pharmacological intervention.
Psychotropic medications offer potential benefits but also risks in post-stroke patients.
Careful consideration of drug selection and monitoring is crucial for optimal outcomes.

Purpose of the Study:

To review the specific clinical implications of using psychotropic medications in stroke patients.
To highlight the importance of accurate diagnosis and appropriate drug selection.
To discuss the avoidance of adverse effects that may impede recovery.

Main Methods:

Literature review focusing on psychopharmacology in the context of stroke.
Analysis of clinical data regarding the use of specific drug classes.
Examination of potential interactions and side effects relevant to stroke recovery.

Main Results:

Antipsychotic, antidepressant, psychostimulant, antimanic, and anxiolytic agents have specific roles in managing stroke-related conditions.
Medication selection must be tailored to individual patient needs and potential interactions.
Monitoring for efficacy and side effects is essential for safe and effective treatment.

Conclusions:

Effective psychopharmacological management in stroke requires a nuanced approach.
Understanding the specific benefits and risks of each agent is critical.
Optimizing medication use can significantly improve functional recovery and quality of life for stroke survivors.